Neoadjuvant nivolumab plus chemotherapy in resectable non‐small‐cell lung cancer in Japanese patients from <scp>CheckMate</scp> 816
Tetsuya Mitsudomi(Kindai University), Fumihiro Tanaka(University of Occupational and Environmental Health Japan), Ives Ntambwe(Bristol-Myers Squibb (United States)), Keisuke Tomii(Kobe City Medical Center General Hospital), Hiroyuki Ito(Kanagawa Prefectural Hospital Organization), Satoshi Oizumi(Hokkaido University), Masahiro Tsuboi(National Cancer Center Hospital East), Jiro Okami(Osaka Medical Center for Cancer and Cardiovascular Diseases), Shinji Atagi(National Institute of Technology, Nara College), Shunichi Sugawara(Sendai Kousei Hospital), Kazuya Takamochi(Juntendo University), Noriaki Sakakura(Aichi Cancer Center), Kaoru Kubota(Nippon Medical School Hospital), Javed Mahmood(Bristol-Myers Squibb (United States)), Junliang Cai(Bristol-Myers Squibb (United States)), Norihiko Ikeda(Tokyo Medical University), Yutaka Shio(Fukushima Medical University Hospital), Morihito Okada(Hiroshima University), Yasuhisa Ohde(Shizuoka Cancer Center)
Cited by 27
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k